Try our beta test site
5 studies found for:    ALXN1210
Show Display Options
Rank Status Study
1 Active, not recruiting An Open-Label, Intrapatient, Dose-Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients With Paroxysmal Nocturnal Hemoglobinuria
Condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Intervention: Biological: Study Drug - ALXN1210
2 Recruiting ALXN1210 Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions: Biological: ALXN1210;   Biological: Eculizumab
3 Not yet recruiting ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
Condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions: Biological: ALXN1210;   Biological: Eculizumab
4 Active, not recruiting A Open-label, Multiple Ascending Dose Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients With Paroxysmal Nocturnal Hemoglobinuria
Conditions: Paroxysmal Nocturnal Hemoglobinuria;   PNH
Intervention: Biological: Study Drug- ALXN1210
5 Recruiting Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
Condition: Atypical Hemolytic Uremic Syndrome (aHUS)
Intervention: Biological: ALXN1210

Study has passed its completion date and status has not been verified in more than two years.